The UK and US have forged a major bilateral deal that will guarantee zero import taxes on British drug exports entering the American market.
The Terms of the Accord
As part of the deal, the UK has committed to boost spending on medicines through the National Health Service (NHS). This pledge guarantees that import taxes on these key goods will stay at zero for a duration of the next three years.
This agreement comes after earlier warnings to significantly raise import taxes on patented pharmaceutical products, with increases floated as high as double the cost.
"This deal with the Britain bolsters the global environment for cutting-edge drugs and establishes long-overdue balance to transatlantic pharmaceutical trade," a release noted.
Commercial Significance
Pharmaceuticals represent one of the Britain's largest export categories to the US, which is clearly the primary destination for large British pharmaceutical firms.
Export figures show that in the one-year period to the end of September, the UK exported medicines worth billions to the US. This figure accounted for nearly one-fifth of total UK exports in that timeframe.
"This agreement safeguards work, increases investment and paves the way for the UK to become a international leader for biotech and pharma," a minister commented.
Key British Pledges
The agreement includes several notable pledges from the UK:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new treatments to be unaffordable by 25%.
- Higher Drug Budget: There is a target to raise overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The sum drug companies must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, refunds exceeded 20%.
Recent Tensions
The pact follows a protracted dispute between the sector and the ministers over spending levels and regulatory access.
The disagreement were intensified by arguments that US patients were paying several times more for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been paused or cancelled, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
A senior figure stated that the NHS had to spend more on medicines, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.
